Figure 3.

VILI is augmented by silencing (si) DIO2 (siDIO2). (A) In vivo silencing effect of custom-designed siDIO2 in lung homogenates was confirmed by Western blotting (inset), quantified by densitometry, and expressed in bar graphs as normalized D2 densitometry in relative units. Significant reduction of D2 expression was observed in siDIO2 pretreated SB mice. D2 level augmented by VILI was markedly reduced by siDIO2 compared with VILI vehicle control (CRTL) or scrambled siRNA (siCTRL) mice. (B) Bronchoalveolar lavage (BAL) protein levels in SB and VILI mice. Significant increase of BAL proteins was observed in siDIO2-pretreated SB or VILI mice compared with CRTL or siCTRL mice. (C) BAL leukocytes (white blood cells [WBCs]) were expressed as 10⁶/ml in SB and VILI mice. A significant increase of BAL leukocytes was observed in siDIO2-pretreated SB or VILI mice compared with CRTL or siCTRL mice. A tidal volume of 30 ml/kg for 4 hours was used for the VILI model, which was evidenced by minimal inflammatory cells observed in SB mice treated with vehicle control (CTRL) or siCTRL, whereas inflammation and protein leak increased in VILI mice (CTRL or siCTRL). siDIO2 (10 mg/kg) or siCTRL was delivered intratracheally 72 hours before the experiments. Results are from at least five independent experiments; *P < 0.05.